Skip to main content
SpringerLink
Log in

Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome

  • POINTS OF VIEW
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

The anti-phospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity, associated with a persistent positivity for anti-phospholipid antibodies (aPL). The current classification criteria for APS include three laboratory tests: lupus anti-coagulant (LA), anti-cardiolipin (aCL), and anti-β2 glycoprotein-I (β2GPI). To date, the therapeutic approach for thrombotic APS mainly centers on long-term anti-coagulation with a vitamin K antagonist (VKA). APS management may represent a challenge for the treating physicians. Patients with different aPL profiles need a tailored risk-stratified approach. Moreover, in patients with recurrent thrombotic events despite therapy with VKA, or in those with microvascular involvement, new therapeutic options are highly needed. In this review, we aim to elucidate recent findings about new aPL specifities, available risk scoring models, and novel therapeutic approaches in APS management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306

    Article  CAS  PubMed  Google Scholar 

  2. Mahler M, Norman GL, Meroni PL, Khamashta M (2012) Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 12(2):313–317

    Article  CAS  PubMed  Google Scholar 

  3. Radin M, Cecchi I, Roccatello D et al (2016) Prevalence and thrombotic risk assessment of anti-domain I beta 2 glycoprotein I antibodies: a systematic review and a meta-analysis. Lupus 25 (abstract supplement 1S)

  4. Sciascia S, Khamashta MA, Bertolaccini ML (2014) New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Curr Rheumatol Rep 16(5)

  5. Ruffatti A, Del Ross T, Ciprian M et al (2011) Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 70(6):1083–1086

    Article  PubMed  Google Scholar 

  6. Galli M, Luciani D, Bertolini G et al (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101(5):1827–1832

    Article  CAS  PubMed  Google Scholar 

  7. Groot PGDE, Lutters B, Derksen RHWM, Lisman T (2005) Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. 1993–1997

  8. Pengo V, Ruffatti A, Legnani C et al (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8(2):237–242

    Article  CAS  PubMed  Google Scholar 

  9. Otomo K et al (2012) Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64(2):504–512

    Article  CAS  PubMed  Google Scholar 

  10. Sciascia S, Sanna G, Murru V et al (2013) GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford) 52(8):1397–1403

    Article  Google Scholar 

  11. Sciascia S, Baldovino S, Schreiber K et al (2016) Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. Clin Mol Allergy 14(1):6

    Article  PubMed  PubMed Central  Google Scholar 

  12. Sciascia S, Khamashta MA, D’Cruz DP (2014) Targeted therapy in antiphospholipid syndrome. Curr Opin Rheumatol 26(3):269–275

  13. Rand JH, Wu X-X, Quinn AS et al (2010) Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115(11):2292–2299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kaiser R, Cleveland CM, Criswell LA (2009) Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 68(2):238–241

    Article  CAS  PubMed  Google Scholar 

  15. Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR et al (2016) Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 3(9):e426–e436

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sciascia S, Giachino O, Roccatello D Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol 30(3):409–413

  17. Erre GL, Pardini S, Faedda R, Passiu G (2008) Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 17(1):50–55

    Article  CAS  PubMed  Google Scholar 

  18. Sciascia S, Naretto C, Rossi D, Bazzan M, Roccatello D (2011) Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus 20(10):1106–1108

    Article  CAS  PubMed  Google Scholar 

  19. Durcan L, Fu W, Petri M (2016) Hypocomplementemia associates with thrombosis in SLE patients with antiphospholipid antibodies. Ann Rheum Dis 75(Suppl2):126

    Google Scholar 

  20. Pengo V, Ruffatti A, Legnani C et al (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8(2):237–242

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, S. Giovanni Bosco Hospital, Piazza del Donatore di Sangue 3, 10154, Turin, Italy

    Savino Sciascia, Massimo Radin & Dario Roccatello

  2. SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy

    Savino Sciascia & Dario Roccatello

  3. UOSD Hematology and Thrombosis Unit, S. Giovanni Bosco Hospital, Turin, Italy

    Mario Bazzan

Authors
  1. Savino Sciascia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Massimo Radin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario Bazzan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dario Roccatello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Savino Sciascia.

Ethics declarations

Conflict of interest

The Authors declare that they have no conflict of interest.

Statement of human and animal rights

Not applicable.

Informed consent

Not applicable.

Funding

None declared.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sciascia, S., Radin, M., Bazzan, M. et al. Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. Intern Emerg Med 12, 1–7 (2017). https://doi.org/10.1007/s11739-016-1596-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-016-1596-2

Keywords

Search

Navigation